Laura Berezin


+1 650 843 5128

Laura Berezin focuses on corporate securities, M&A and complex corporate finance transactions, with a particular emphasis on representing clients in the life sciences industry. She represents public and private corporations, investment banks, venture capital funds, and financial institutions both in the United States and Europe in a variety of capital market transactions, including public offerings, private placements, PIPES and 144A transactions. Laura has extensive experience in representing life science companies in spin-outs and other domestic and cross-border M&A. Her general corporate practice includes formation and financing activities, securities compliance, public company disclosure and corporate governance matters. She also has extensive experience in counseling publicly-traded life sciences companies and their boards of directors. Laura is also a member of BIO's Emerging Company Governing Board. 

Download full bio


  • Applied Therapeutics $40 Million IPO 

  • Immune Design Sale to Merck for $300 Million 

  • Harpoon Therapeutics - $76 Million IPO 

  • Kezar Life Sciences – $86 Million IPO 


  • University of Pennsylvania Law School
    JD, 1992

  • University of California, Berkeley
    BS, Phi Beta Kappa, with high honors

Admissions & Credentials



+1 650 843 5128 office

3175 Hanover Street
Palo Alto, CA 94304-1130